- Home
- GROV vs STTK Comparison
GROV vs STTK Comparison
Compare GROV & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GROV
- STTK
- Stock Information
- Founded
- GROV 2016
- STTK 2016
- Country
- GROV United States
- STTK United States
- Employees
- GROV N/A
- STTK N/A
- Industry
- GROV Package Goods/Cosmetics
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- GROV Consumer Discretionary
- STTK Health Care
- Exchange
- GROV Nasdaq
- STTK Nasdaq
- Market Cap
- GROV 59.0M
- STTK 56.8M
- IPO Year
- GROV N/A
- STTK 2020
- Fundamental
- Price
- GROV $1.42
- STTK $1.16
- Analyst Decision
- GROV Buy
- STTK Hold
- Analyst Count
- GROV 1
- STTK 3
- Target Price
- GROV $2.00
- STTK $2.00
- AVG Volume (30 Days)
- GROV 237.9K
- STTK 135.7K
- Earning Date
- GROV 03-05-2025
- STTK 02-27-2025
- Dividend Yield
- GROV N/A
- STTK N/A
- EPS Growth
- GROV N/A
- STTK N/A
- EPS
- GROV N/A
- STTK N/A
- Revenue
- GROV $213,781,000.00
- STTK $6,435,000.00
- Revenue This Year
- GROV N/A
- STTK $313.04
- Revenue Next Year
- GROV $0.84
- STTK N/A
- P/E Ratio
- GROV N/A
- STTK N/A
- Revenue Growth
- GROV N/A
- STTK 382.75
- 52 Week Low
- GROV $1.19
- STTK $0.94
- 52 Week High
- GROV $2.44
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- GROV 50.16
- STTK 48.52
- Support Level
- GROV $1.32
- STTK $1.06
- Resistance Level
- GROV $1.95
- STTK $1.24
- Average True Range (ATR)
- GROV 0.14
- STTK 0.09
- MACD
- GROV -0.00
- STTK -0.00
- Stochastic Oscillator
- GROV 19.70
- STTK 30.30
About GROV Grove Collaborative Holdings Inc.
Grove Collaborative Holdings Inc is engaged in providing consumer products. It offers Cleaning accessories, Home and Pantry, Personal care products, Pets supplements and Other products.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.